With $8M seed round, Waltham biotech puts new twist on ‘exon-skipping’

Unlike Sarepta Therapeutics, which makes a drug that skips over faulty exons — parts of genes that encode proteins — Skyhawk Therapeutics is developing treatments for diseases that are caused by exon-skipping.

Source: bizjournals.com Health Care:Biotechnology headlines - January 23, 2018 Category: Biotechnology Authors: Max Stendahl Source Type: news